Our mission

Our Mission is the development of Gold-ion based inhaled therapies for various lung disorders. 

We use the well-established efficacy and safety of Gold-ions (in the Aurovir project it is aurothioglucose) in the therapy of rheumatoid arthritis and re-discover it for use in infectious and inflammatory pulmonary diseases using an innovative new formulation process for inhalation. 

We combine the gold-ions with other molecules to maximize their therapeutic potential as we develop the portfolio in lung diseases further. 

Re-designing is more than repurposing

The pharmacologically active gold1+-ion is complementary to many other drugs with anti-bacterial, anti-viral, anti-inflammatory and anti-cancer properties.

The first focus of Aurovir Pharma GmbH is the development of a highly innovative medicine to treat viral pulmonary infections via inhalation, based on aurothioglucose (project title: Aurovir).

Further promising indications are mixed viral-bacterial infections; inflammatory diseases (ARDS, Asthma/COPD) and lung cancer.

The development of inhalable, gold containing combinations for these indications means the introduction of a fundamentally new concept and will prepare the way to treatments with highly increased efficacy and specificity in many lung diseases.

Why Aurovir is a golden opportunity for lung diseases

Existing literature hints to several therapeutic options for gold drugs in lung diseases with an unmet medical need.

Both pharmacodynamic and pharmacokinetic properties of gold medicines are unique.

They target specifically sulfur containing protein structures, among them important viral proteins and inflammatory key regulators, which are responsible for the “cytokine storm” in ARDS.

„The golden bullet“: gold ions perfectly fit into metal binding sites of active centers of regulatory enzymes, so that they sit at the right position exert their activity.

Since they are not metabolized there are no problems with toxic degradation products.

With a long on target half-life time, gold drugs remain longer in position to supports organ specific applications

Therefore they are ideal candidates for drug-drug combinations.